Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373179 | 0.98 | HTT (0.38) | CYP1A2HTTCHRM3NCF1 | |
| SCHEMBL4373968 | 0.91 | HTT (0.39) | HTTCHRM3NCF1 | |
| SCHEMBL2444679 | 0.91 | HTT (0.39) | HTTCHRM3NCF1 | |
| SCHEMBL12308321 | 0.91 | HTT (0.39) | HTTCHRM3NCF1 | |
| Hydrochloric Acid SCHEMBL19067205 | 0.89 | HTT (0.38) | HTTCHRM3NCF1 | |
| Hydrochloric Acid SCHEMBL20608334 | 0.89 | HTT (0.38) | HTTCHRM3NCF1 | |
| SCHEMBL13337091 | 0.84 | CYP1A2 (0.35) | CYP1A2HTTCHRM3 | |
| SCHEMBL23371066 | 0.83 | KMT2A (0.41) | CYP1A2HTTCHRM3KMT2ATP53 | |
| SCHEMBL22820734 | 0.83 | HTT (0.36) | CYP1A2HTTNCF1 | |
| SCHEMBL21398646 | 0.83 | KMT2A (0.41) | CYP1A2HTTCHRM3KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | CYP1A2 111/4885HTT 2539/4885EPHX1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.